Tru Niagen Review: Ingredients, Evidence, Versions and Value

Tru Niagen is one of the clearest NR products to connect to the published ingredient literature because it identifies NIAGEN nicotinamide riboside chloride. The current 300 mg capsule is a straightforward way to compare a label with several human biomarker studies. That research connection is a strength, while it does not establish that the product improves every advertised health outcome.

This is a desk-based assessment of current official labels, prices and primary research, checked October 22, 2026. We did not conduct a personal-use trial or independent laboratory assay. Biohack Blueprint has an affiliate relationship with DoNotAge; that relationship is relevant when considering our alternative recommendations.

The current 300 mg label

The official product page lists a one-vegetarian-capsule serving with 300 mg NIAGEN, identified as nicotinamide riboside chloride. Other listed ingredients are microcrystalline cellulose, hypromellose and vegetable magnesium stearate.

The site currently offers 30-, 90- and 180-count options. A generic supplement-facts panel may display one pack's serving count while the purchase selector offers several packs, so match the selected variant with the bottle being ordered.

Prices are a dated US snapshot. Shipping, taxes, regional availability and subscription terms can change the delivered total.

NIAGEN ingredient evidence versus finished-product evidence

A branded ingredient makes research traceability easier when the paper identifies that ingredient and formulation. It does not turn every publication on NAD metabolism into a trial of every current Tru Niagen SKU.

The early oral NR study investigated single-dose pharmacokinetics and changes in the NAD metabolome. The later 140-person trial tested NR chloride at 100, 300 and 1,000 mg/day for eight weeks and found dose-dependent whole-blood NAD+ increases. ^{[1] [2]}

For the 300 mg group, the reported two-week NAD+ increase was approximately 51%. That is a useful connection to the label amount. It is not a promise that every buyer will obtain the same percentage, feel a particular improvement or live longer.

A paper should still be checked for its exact intervention, population, duration, comparator and funding. The number of publications using an ingredient is not the same as the number of independent successful clinical-outcome trials.

What benefits are reasonable to expect?

The best-supported expectation is a change in NAD-related biomarkers, with individual variability. Reliable improvements in energy, memory, weight or lifespan are much less established.

The 2026 MCI study roughly doubled blood NAD+ without improving cognition or total cerebral blood flow. The long-COVID study also raised NAD+ without improving cognition, fatigue, sleep or mood versus placebo. These findings are relevant to broad everyday-energy and brain-health claims, even though the populations differ from healthy consumers. ^{[3] [4]}

NOPARK's phase III result did not support a disease-modifying Parkinson's benefit. A well-identified ingredient can have useful biomarker evidence while failing to improve a particular clinical outcome. ^[5]

Our benefits review explains the indication-specific results. A product review should not replace those results with a list of pathways.

The 300 mg product is not the whole Tru Niagen range

The current official range also includes a 150 mg product, 300 mg stick packs, Pro 1,000 mg and other line extensions. Do not assume that every version has the same serving count, co-ingredients, directions or cost per day.

Pro's larger front-label amount does not establish proportionately greater clinical benefit. The dose-response evidence concerns a blood biomarker, not a universal increase in health benefit with each additional milligram. ^[2]

Likewise, oral capsules should not inherit claims from intravenous products or topical skincare under related branding. Molecule, formulation and route all need to match the evidence. The NR-versus-NAD+ guide explains this common source of confusion.

Price and pack-size arithmetic

Using the current US one-time prices, the approximate cost per capsule is:

These are arithmetic comparisons, not recommended daily intakes or a guarantee of future prices. They exclude shipping and tax. Subscription offers should be compared using their actual terms rather than assumed to stack with every promotion.

A larger pack lowers the checked per-capsule price but increases upfront commitment. Whether that is good value depends on product suitability, tolerability and the purpose of use, not simply the discount percentage.

Quality badges: what they can and cannot establish

The manufacturer displays several quality and assurance statements. These should be read according to their actual scope: ingredient identity, manufacturing practice, an external test, certification and clinical efficacy are different things.

A badge does not establish that Biohack Blueprint independently tested the current lot. Nor does an ingredient notification mean drug-style FDA approval of anti-aging efficacy. FDA's supplement framework differs from drug approval.

For a concrete verification request, ask for the document matching the actual finished product and lot, the laboratory, test date, method and relevant specifications. A report on a historical lot or raw ingredient can provide useful background without completely verifying a current bottle.

Directions and dose escalation

The current page includes directions allowing more than one daily capsule and broader safety language. Those are manufacturer statements, not our conclusion that every adult should escalate intake or that a maximum is universally appropriate.

A trial amount and a consumer's suitable amount are different questions. The dosage guide explains the range of human exposures and why short supervised high-dose studies do not establish indefinite high-dose safety.

If no meaningful benefit is apparent, increasing the amount is not an evidence-based substitute for reassessing the original goal. Higher NAD+ is not a universal treatment target.

Side effects and who needs individual advice

The eight-week trial did not find a significant difference in reported adverse events versus placebo. Its selected population and short duration still limit what it can establish about rare, delayed or individual effects. ^[2]

Pregnancy, breastfeeding, childhood, significant illness and complex medicines need appropriate individual consideration. For active cancer treatment, discuss the precise product with the oncology team rather than relying on a broad “vitamin” label. The safety guide and cancer dossier explain the evidence boundaries.

A combination product elsewhere in the range may require additional ingredient-specific assessment. Do not assume that the base capsule's evidence settles every line extension.

How it compares with the main alternatives

Life Extension's 100 mg and 300 mg Cell Regenerator products also identify NIAGEN NR chloride, with different pack sizes, excipients and checked prices. They are useful comparisons when the priority is a named conventional ingredient. See the Life Extension review.

Thorne NiaCel 400 uses NR hydrogen malate with betaine, while ResveraCel adds resveratrol and quercetin phytosome. Their salt mass and complete formulas should not be compared as though all front-label milligrams represent identical NR exposure.

Our DoNotAge review evaluates the simpler formulation proposition and openly reports the current dose-label inconsistency. Our commercial preference does not establish DoNotAge's clinical superiority over NIAGEN products.

Who is Tru Niagen best suited to?

It is a reasonable shortlist option for someone who prioritizes an identifiable NR chloride ingredient, a straightforward 300 mg capsule and a clear connection to published biomarker research. It is a less compelling purchase if the decision depends on a guaranteed subjective energy effect, dementia prevention or proven life extension.

The main strengths are ingredient traceability and a clear core label. The main limitations are uncertain clinical benefit for many common goals and a meaningful recurring cost. The best-NR comparison places those tradeoffs beside current alternatives without treating a brand name or publication count as proof of universal efficacy.